Ather­sys’ woes con­tin­ue as As­pire Cap­i­tal ax­es its re­la­tion­ship with the biotech

While Ather­sys has been in the pen­ny stock twi­light zone since 2021, the com­pa­ny has hit sev­er­al ma­jor speed bumps in the past few months and this lat­est piece of news is an­oth­er hit against the biotech.

On Fri­day, the Cleve­land-based biotech an­nounced that its eq­ui­ty pur­chase agree­ment with As­pire Cap­i­tal Fund has been ter­mi­nat­ed.

Ac­cord­ing to the com­pa­ny, there were sev­er­al dis­cus­sions with As­pire Cap­i­tal be­fore the biotech re­ceived a no­tice on Wednes­day of the im­me­di­ate ter­mi­na­tion of the agree­ment, which had been in place since May 12.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER